A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma

• Published in: The oncologist (Dayton, Ohio) Vol. 29; no. 3; pp. 270 - e413
• Main Authors: Yu, Shawn, Yu, Menggang, Keane, Barry, Mauro, David M, Helft, Paul R, Harris, William P, Sanoff, Hanna K, Johnson, Matthew S, O’Neil, Bert, McRee, Autumn Jackson, Somasundaram, Ashwin
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01.03.2024
• Subjects: Blood clot; Cancer; Care and treatment; Clinical Trial Results; Combined modality therapy; Development and progression; Hepatoma; Immunotherapy; Liver; Liver cancer; Medical prognosis; Methods; Pilot projects; Prognosis; Radiotherapy; Rare earth metals; Thrombosis; Transplantation; United States; pembrolizumab; glass Y90 radioembolization; hepatocellular carcinoma; immunotherapy; TARE

Abstract Background Combination checkpoint inhibition therapy with yttrium-90 (Y90) radioembolization represents an emerging area of interest in the treatment of advanced hepatocellular carcinoma (HCC). HCRN GI15-225 is an open-label, single-arm multicenter, pilot study (NCT03099564). Methods Eligib...